Compare Rivian Automotive, Inc. (RIVN) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rivian Automotive, Inc. vs TG Therapeutics Inc — how do they compare? Rivian Automotive, Inc. trades at $16.04 (market cap $23.41B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: Rivian Automotive, Inc. is far larger — about 2.7× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Rivian Automotive, Inc. nearer its low. Which is the better fit depends on your goals.
| RIVN | TGTX | |
|---|---|---|
Market Cap | $23.41B | $8.53B |
Sector | Consumer Cyclical | Health |
52-Week High | $22.45 | $59.06 |
52-Week Low | $12.50 | $26.94 |
Enterprise Value | $23.45B | $8.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rivian Automotive (RIVN) trades at $16.17, up 2.73% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $18.70. The company continues to report significant net losses but has shown improvement in revenue growth and gross profit margins, while recent news highlights strong demand for the R2 SUV and advancements in autonomy capabilities.
The outlook for RIVN hinges on successful R2 production scaling and path to profitability, with upside potential from current levels but high execution risk amid competitive EV market pressures and persistent cash burn requiring ongoing financing.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
